课题基金 / 基金详情

Fully Automatic ROP Screening System: NeoScan

Fully Automatic ROP Screening System: NeoScan
全自动 ROP 筛查系统:NeoScan
批准号:
8900708
负责人:
Eduardo Simon Barriga
金额:
$61.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2017-05-31

项目摘要

项目成果

Eduardo Simon Barriga的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请者提供):这个第二阶段的项目是由目前与早产儿视网膜病变(ROP)筛查相关的问题推动的。ROP是导致婴儿失明的主要原因。近年来,患ROP风险的婴儿数量一直在增加。在美国,早产率从1981年的9.4%上升到2010年的12%,总共有50多万早产儿。早产儿疾病的管理在很大程度上取决于及时的筛查和干预。不幸的是,ROP筛查的报销水平较低,偏远地区ROP筛查设备不足,以及长期暴露于医疗事故行动中,使得难以为有风险的新生儿提供适当的护理。为了缓解这些问题,VisionQuest Biomedical LLC及其合作伙伴奥克兰大学(MI)和南得克萨斯州视网膜研究所(RIST)将演示和测试NeoScan,这是一系列旨在改善ROP管理和检测的软件产品。NeoScan由两个产品组成:NeoScan-Assisted和NeoScan-Detect。NeoScan-Assistate旨在通过准确量化血管曲折和口径,提高生产力并减少新生儿保健提供者在解释时的可变性,这些因素已被证明与晚期ROP的存在相关。NeoScan-Assistate的目标是减少晚期ROP诊断的变异性,并为新生儿ROP的准确筛查和分期提供工具。NeoScan-Detect旨在自动识别需要眼科医生进一步检查的婴儿。该项目的目标将通过三个具体目标来实现。在目标1中,我们将通过生产在该项目第一阶段开发的方法来完成NeoScan-Assisted的产品开发。在目标2中,将进行一项前瞻性临床研究,以评估NeoScan-Assisted的有效性,并为NeoScan-Detect的有效性提供数据。在目标3中,我们将演示作为NeoScan-Detect的一部分的图像处理技术。在此第二阶段项目结束时,我们将准备提交FDA 510(K)的NeoScan-Assistate上市许可,在提交的同时,我们将进行临床试验,以证明NeoScan-Detect的安全性和有效性,为FDA提交该产品的市场许可做准备。
英文摘要
 DESCRIPTION (provided by applicant): This Phase II project is motivated by current issues associated with screening for retinopathy of prematurity (ROP). ROP is the leading cause of blindness in infants. In recent years the number of infants at risk for ROP has been increasing. In the United States, the rate of prematurity has risen from 9.4% of all births in 1981 to 12% in 2010, for a total of over 500,000 preterm births. Preterm neonate disease management depends largely on timely screening and intervention. Unfortunately, low reimbursement levels for ROP screening, insufficient equipment for ROP screening in remote locations, and long-term exposure to medical malpractice actions make it difficult to provide appropriate care to neonates at risk. To mitigate these problems, VisionQuest Biomedical LLC and its collaborators, Oakland University (MI) and the Retina Institute of South Texas (RIST), will demonstrate and test NeoScan, a family of software products aimed at improving the management and detection of ROP. NeoScan consists of two products: NeoScan-Assist and NeoScan-Detect. NeoScan-Assist is aimed at increasing the productivity and reducing the variability in interpretation by th neonatal healthcare providers through accurate quantification of vasculature tortuosity and caliber, factors that have been demonstrated to correlate with the presence of advanced stages of ROP. The objectives of NeoScan-Assist are to reduce variability in the diagnosis of advanced stages of ROP and to provide a tool for accurate screening and staging of ROP in neonates. NeoScan-Detect is aimed at automatically identifying infants that need further examination by an ophthalmologist. The objectives of this project will be accomplished through three specific aims. In Aim 1 we will finalize the product development of NeoScan-Assist by productizing the methods developed during Phase I of this project. In Aim 2, a prospective clinical study will be performed to evaluate the effectiveness of NeoScan-Assist and to provide data for validation of NeoScan- Detect. In Aim 3 we will demonstrate the image processing techniques that will be part of NeoScan-Detect. At the end of this Phase II project we will be ready to submit an FDA 510(k) market clearance for NeoScan-Assist, and, in parallel with that submission, we will perform a clinical trial to demonstrate the safety and effectiveness of NeoScan-Detect in preparation for an FDA market clearance submission of that product.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fully Automatic ROP Screening System: NeoScan
  • 批准号:
    8639682
  • 项目类别:
  • 资助金额:
    $17.23万
  • 财政年份:
    2014
  • 负责人:
    Eduardo Simon Barriga
  • 依托单位:
Stroke Risk Stratification through Plaque Motion Analysis of Longitudinal Carotid
  • 批准号:
    7926175
  • 项目类别:
  • 资助金额:
    $19.99万
  • 财政年份:
    2010
  • 负责人:
    Eduardo Simon Barriga
  • 依托单位:
海外基金